The company, whose shares slumped earlier on Wednesday after it reported weaker-than-expected revenue from a new prostate cancer drug, said the increase was largely a result of various performance-linked incentive payouts.
Narasimhan has been running Novartis since 2018 and during that time he has spun off a non-core division, restructured some operations and made a number of acquisitions, not all of which ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.